The Life Sciences team advised Engitix Ltd on its licensing and collaboration agreement with Takeda Pharmaceutical Company Limited to discover and develop novel therapeutics for advanced fibrotic liver diseases, including non-alcoholic steatohepatitis.
Engitix is a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix platform.
Under the terms of this agreement, Engitix and Takeda will collaborate in the confirmation and validation of targets and preclinical development of therapeutics in liver fibrosis using Engitix’s unique extracellular matrix discovery platform. Takeda will have exclusive rights to develop and commercialise clinical candidates generated against validated targets derived from the collaboration. Engitix will receive an upfront payment, with additional near-term payments based on the confirmation and functional validation of selected targets. Engitix will be eligible to receive more than $500 million for the achievement of preclinical, development, regulatory, and commercial milestones, as well as further royalty payments upon sales of commercialised products.For more details, read the press release and articles in Endpoints and The Pharma Letter.